DIAsource ImmunoAssays S.A.

DIAsource ImmunoAssays seeks patent for Monoclonal Antibodies for detection of Vitamin D.

DIAsource ImmunoAssays (formerly BioSource) has filed a patent application covering technology for monoclonal antibodies against 25 OH Vitamin D2 and D3 (Total Vitamin D) and use of such antibodies in immunological assays. The use of monoclonal antibodies that both recognize 25 OH Vitamin D2 and 25 OH Vitamin D3 instead of polyclonal antibodies is a major step forward to ensure long-term reliability of the assays.

DIAsource is using these antibodies internally to develop different assay formats and will bring these assays into the market before end of 2010. Simultaneously DIAsource offers licenses to other diagnostic companies to use these antibodies to develop assays on automated systems.

DIAsource has been on the Vitamin D market for more than 15 years with RIA assays for 25 OH Vitamin D3 and 1,25 (OH)2 Vitamin D. With the new monoclonal antibodies and a new releasing step DIAsource will be ready to offer isotopic and non-isotopic (ELISA) assays that will recognize both 25 OH Vitamin D2 and D3. The ELISA assay will also become available on an open automated system in the beginning of 2011.

With these new assays DIAsource will become a direct competitor to the major players in this market Diasorin and IDS.

DR. Jozef Vangenechten, CEO